Skip to content

Enovis 公司

US · ENOV #3237 按市值排名
19.59 +0.24 +1.24%
实时 - 追踪5344个代码 - 心跳于499秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 0.69 低于历史水平 第13百分位
5年平均 0.81 · 在Medical Devices中排名第14/125
市盈率 -0.91 高于历史水平 第72百分位
5年平均 -6.83 · 前瞻 -86.61
市销率 0.44 低于历史水平 第0百分位
5年平均 1.12 · 前瞻 0.42 · 在Medical Devices中排名第15/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
Enovis 公司 (ENOV) 1.13B -1.02 0.76 0.00%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★★ 合理价值32.15 经济护城河None 不确定性High

当前股价低于晨星合理价值估算64.1%。

合理价值

Enovis Corp earns a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 45% discount to our quantitative fair value estimate of $32.15 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 144.4%, which falls in the top 20% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

The firm's balance sheet is an additional encouraging factor. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. The firm's EBITDA/interest coverage ratio of -22.0, for example, falls in the bottom 10% compared with global peers. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. This characteristic further promotes our favorable price/fair value ratio.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

Enovis 公司 讨论区 0 条评论

发表评论